 | • レポートコード：D0-MOR-AP0677 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、高脂血症治療薬の世界市場について調査・分析した資料で、高脂血症治療薬の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The Hyperlipidemia Drugs Market is expected to register a CAGR of 2.3% during the forecast period. The hyperlipidemia drug market is growing at a good rate attributing to increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia. Moreover, upcoming patent expiration lead to genericization in the market, mostly in statins and cholesterol absorption inhibitors which further fuel the market to certain extent. Several product launches are also anticipated to drive the hyperlipidemia drugs market. For instance, Recent launch of Repatha (2016) and Praluent (2017) is likely to change the current therapeutic scenario due to their improved efficacy and safety profile.
Key Market Trends
Statin Hyperlipidemia Drugs Segment is Expected to witness healthy growth in the Hyperlipidemia Drugs Market
Statins is expected to witness a healthy CAGR owing to surge in the incidence of cardiovacular disorders. Statins are the first line therapy which reduces the risk associated with heartattacks which also contributes to the growth of the market. Furthermore Benefits such as improved endothelial function, enhance the stability of atherosclerotic plaques , reduce the amount of inflammation and damage done to cells due to oxidative stress is also resposible for preferring of statins and drive the market. Moreover, PCSK9 inhibiotrs is also expected to grow in forcasted period attributed to drastic reduction of LDL levels in the blood.
Europe is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Europe is expected to hold a major market share in the global Hyperlipidemia Drugs market due to increasing prevalence of hypercholesteremia, increasing healthcare expenditure and presence of well-established healthcare infrastructure. Moreover, surge in obese population in this region leading to adopt hyperlipidemia drugs for diagnostic purpose is also anticipated to contribute to promote market growth.
Competitive Landscape
The Hyperlipidemia Drugs Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Dr. Reddy’s Laboratories, Mylan, Amgen, Sanofi, AstraZeneca, Merck & Co., Inc, and DAIICHI SANKYO COMPANY, LIMITED.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in Awareness About Risk of Cardiovascular Diseases
4.2.2 Emergence of Novel Drug Classes
4.2.3 Rise in Prevalence of Hyperlipidemia Across the Globe
4.3 Market Restraints
4.3.1 Upcoming Patent Expirations of Drugs
4.3.2 Regulatory Framework
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Statins
5.1.2 Cholesterol Absorption Inhibitors
5.1.3 Bile Acid Sequestrants
5.1.4 PCSK9 Inhibitors
5.1.5 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Mylan NV
6.1.2 Amgen
6.1.3 Sanofi
6.1.4 DAIICHI SANKYO COMPANY, LIMITED
6.1.5 AstraZeneca
6.1.6 ESPERION Therapeutics, Inc
6.1.7 Merck & Co., Inc
6.1.8 Pfizer Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS